The International PERForator ANeurysm Registry (PERFAN)
NCT ID: NCT06189014
Last Updated: 2024-01-03
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
300 participants
Study Classification
OBSERVATIONAL
Study Start Date
2023-11-09
Study Completion Date
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this international, multicenter, mixed retrospective-prospective, exploratory, observational study is to establish an international registry to fill the knowledge gap created by the rarity of lenticulostriate and basilar perforator aneurysms and the resulting lack of knowledge about their natural history, diagnostic evaluation, management, and clinical outcomes. Specifically, comparative analyses of outcomes in patients with intracranial perforator aneurysms treated conservatively, endovascularly, and surgically will be performed. The study will also evaluate the size and location of lenticulostriate and basilar intracranial perforator aneurysms, collect information on the specific type of endovascular treatment used, compare patients with predominantly perimesencephalic subarachnoid hemorrhage (SAH) who have a perforator aneurysm to those without, and evaluate spontaneous occlusion in conservatively treated aneurysms. Core lab analysis of these aneurysms on various imaging modalities will be performed at the Inselspital and changes in aneurysm characteristics over time will be documented. In addition, the relationship between baseline characteristics and aneurysm characteristics on the incidence of hemorrhage will be examined. The study will involve approximately 20-30 centers worldwide with an estimated total sample size of 200-300 patients by 2025.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Natural History With Focus on Oncological Risk Evaluation in Pediatric Patients With PTEN Pathogenic Variants
NCT06805734
PTEN Hamartoma Syndrome
RECRUITING
Neurosurgical Outcome Network
NCT06724029
Aneurysms
Arteriovenous Malformations
Cavernomas
+20 more
RECRUITING
Prediction of Sphenoid Septation in MRI Compared With CT and Intraoperative Findings During Endoscopic Pituitary Adenoma Surgery
NCT03624114
Pituitary Adenoma
COMPLETED
European Registry for Myeloproliferative Neoplasms (MPNs) - Update of ERNEST Study
NCT04153305
Myelofibrosis
COMPLETED
Evaluation of New Biomarkers Predictive of Efficacy Betablockers in PEComa and Vascular Pediatric Tumors
NCT02334930
PEComa
Hemangioma
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Background and current state of research
Lenticulostriate and basilar perforator aneurysms are extremely rare subtypes of intracranial aneurysms. Recent years have seen an increase in their diagnosis due to advancements in imaging technology. However, their low incidence has left a significant gap in the understanding of their natural history, diagnostic evaluation, management, and clinical outcomes. To date, the available literature consists mainly of case reports or small case series, with only a limited number of systematic reviews, such as those on lenticulostriate aneurysms (112 cases) and basilar perforator aneurysms (54 patients).
The most common presentation of perforator aneurysms is rupture, although unruptured aneurysms may be diagnosed as an incidental finding or as the cause of compressive symptoms. Initial angiography fails to identify approximately 30%-60% of perforator aneurysms. Various treatment approaches have been reported, including surgery and various endovascular techniques such as coiling, embolization with liquid embolic agents, flow-diverters, and even electrothrombosis with a microguidewire. However, all invasive strategies have inherent periprocedural risks that must be carefully weighed against the reported overall high rate of favorable outcomes in conservatively managed patients.
Despite the growing interest and knowledge in this field, an international multicenter registry that includes baseline patient characteristics, imaging, follow-up protocols, treatment strategies, and outcomes for both ruptured and unruptured intracranial perforator aneurysms is still lacking.
2. Research questions, hypotheses and aims
The research questions of this exploratory study are:
* To conduct a comparative analysis of clinical characteristics and outcomes among patients with intracranial lenticulostriate and basilar perforator aneurysms treated conservatively, endovascularly, and surgically.
* To assess the size and exact location of lenticulostriate and basilar intracranial perforator aneurysms.
* To gather information regarding the specific type of endovascular treatment employed.
* To compare patients with predominantly perimesencephalic SAH harboring a perforator aneurysm and those without an aneurysm.
* To investigate the occurrence of spontaneous occlusion in aneurysms treated conservatively.
* To perform a core lab analysis of lenticulostriate and basilar intracranial perforator aneurysms using different imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), 2D digital subtraction angiography (DSA), and 3D DSA.
* To review and document observed changes of lenticulostriate and basilar perforator aneurysms (e.g. size) on follow-up imaging.
* To examine the association between aneurysm size and the incidence of bleeding.
3. Methods
3.1 Study population
This is an international, multicenter, mixed-retrospective-prospective exploratory observational study.
So far, in Switzerland, the Inselspital, the University Hospital Basel, the University Hospital Lausanne, the Regional Hospital of Lugano and the Cantonal Hospital St. Gallen are participating in this study and have received ethical approval. In addition, since the start of the study in early November 2023, already 15 international centers have expressed their interest in participating. More centers worldwide will be contacted via a distribution list \[European Society of Minimally Invasive Neurological Therapy (ESMINT); Society of Neurointerventional Surgery (SNIS)\] and invited to participate. The investigators estimate that approximately 20-30 centers worldwide will participate with an estimated total sample size of 200-300 patients by 2025. The analysis will be based on a survey (see below for included data) specifically designed for this study and completed by local neuroradiologists, neurologists or neurosurgeons involved in the management of intracranial perforator aneurysms. The primary treating physician will review the clinical records of patients with intracranial perforator aneurysms treated conservatively, endovascularly, or surgically. Study lead and coordination as well as radiological and statistical analysis will be performed by the team at the Inselspital, Bern, Switzerland.
3.2 Baseline characteristics, imaging variables, treatment variables, and outcome variables
Data include:
* Age, sex, relevant comorbidities such as e.g. hypertension, arteriovenous malformation (AVM), Moya-Moya, initial clinical presentation (incidental vs. hemorrhagic). In case of hemorrhagic presentation the type of bleeding \[SAH, perimesencephalic subarachnoid hemorrhage (pmSAH), intraventricular hemorrhage (IVH), or intracerebral hemorrhage (ICH)\] will be documented.
* Type of initial diagnostic modality (CT, MRI, DSA).
* Perforator aneurysm identified on initial diagnostic modality.
* Type of treatment (surgical vs. endovascular). In case of endovascular treatment specific type \[coiling, n-butyl cyanoacrylate (NBCA), ethylene vinyl alcohol (EVOH), flow-diverter, Electro-coagulation, other\].
* Pre- and post-treatment modified Rankin Scale (mRS).
Clinical endpoints include:
* mRS at 3 months after initial diagnosis of an intracranial perforator aneurysm
* mRS at last follow-up (including time-point of last follow-up after diagnosis)
* Rupture/re-rupture of the index aneurysm as a time-event outcome
Safety endpoints include:
* Death during the acute hospital stay
* Death up to 90 days (related to the index aneurysm)
* Ischemic stroke (imaging based)
* Periprocedural and postprocedural complications in patients submitted to endovascular or surgical treatment.
Efficacy Endpoint
• For patients receiving treatment, assessment of aneurysm occlusion after treatment and available follow-ups.
3.3 Data transfer and storage (Medical-Blocks® and REDCap)
Imaging data from all external participating centers will be securely transferred via and stored on Medical-Blocks® (https://mb-neuro.medical-blocks.ch). This cloud-based platform for storage, anonymization and exchange of medical images in the neuro field (MB-Neuro) is provided by the Inselspital Bern. The platform provides the necessary interfaces to communicate with other secure and advanced IT environments via various Application Programming Interfaces (APIs). Secure Sockets Layers (SSL) with 256-bit encryption is used, which complies with the regulations of KlinV. (Verordnung über klinische Versuche) Art. 18 and HFV (Humanforschungsverordnung) Art. 5 of the Swiss Ordinance on the Storage of Health-Related Personal Data and Biological Materials. The clinical datasets will be provided in an anonymized fashion (matching the anonymized imaging data) by the physician primarily involved in patient management from the participating centers and entered and stored in REDCap.
4. Sample size and statistical analyses
This is an exploratory study. The investigators estimate that approximately 20-30 centers worldwide will participate with an estimated total sample size of 200-300 patients.
Categorical variables will be presented as numbers and percentages, and continuous variables as medians, interquartile range (IQR). Fisher's exact will be used for categorical and Mann-Whitney U test or Kruskal-Wallis test for continuous variables. Logistic regression results will be displayed as odds ratios (OR) for simple regression or adjusted OR (aOR) for multinomial regression analyses, with their corresponding 95% confidence intervals (CIs). As this is an exploratory study, no conclusions about significance can be drawn. Therefore, a p-value \< 0.05 will be interpreted as a trend. All analyses will be performed using established statistic software, including R 4.01 or newer, Python 3.83 or newer, Stata 16 and/or Statistical Package for the Social Sciences (SPSS) 27.00 or newer.
Lenticulostriate and basilar perforator aneurysms are extremely rare subtypes of intracranial aneurysms. Recent years have seen an increase in their diagnosis due to advancements in imaging technology. However, their low incidence has left a significant gap in the understanding of their natural history, diagnostic evaluation, management, and clinical outcomes. To date, the available literature consists mainly of case reports or small case series, with only a limited number of systematic reviews, such as those on lenticulostriate aneurysms (112 cases) and basilar perforator aneurysms (54 patients).
The most common presentation of perforator aneurysms is rupture, although unruptured aneurysms may be diagnosed as an incidental finding or as the cause of compressive symptoms. Initial angiography fails to identify approximately 30%-60% of perforator aneurysms. Various treatment approaches have been reported, including surgery and various endovascular techniques such as coiling, embolization with liquid embolic agents, flow-diverters, and even electrothrombosis with a microguidewire. However, all invasive strategies have inherent periprocedural risks that must be carefully weighed against the reported overall high rate of favorable outcomes in conservatively managed patients.
Despite the growing interest and knowledge in this field, an international multicenter registry that includes baseline patient characteristics, imaging, follow-up protocols, treatment strategies, and outcomes for both ruptured and unruptured intracranial perforator aneurysms is still lacking.
2. Research questions, hypotheses and aims
The research questions of this exploratory study are:
* To conduct a comparative analysis of clinical characteristics and outcomes among patients with intracranial lenticulostriate and basilar perforator aneurysms treated conservatively, endovascularly, and surgically.
* To assess the size and exact location of lenticulostriate and basilar intracranial perforator aneurysms.
* To gather information regarding the specific type of endovascular treatment employed.
* To compare patients with predominantly perimesencephalic SAH harboring a perforator aneurysm and those without an aneurysm.
* To investigate the occurrence of spontaneous occlusion in aneurysms treated conservatively.
* To perform a core lab analysis of lenticulostriate and basilar intracranial perforator aneurysms using different imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), 2D digital subtraction angiography (DSA), and 3D DSA.
* To review and document observed changes of lenticulostriate and basilar perforator aneurysms (e.g. size) on follow-up imaging.
* To examine the association between aneurysm size and the incidence of bleeding.
3. Methods
3.1 Study population
This is an international, multicenter, mixed-retrospective-prospective exploratory observational study.
So far, in Switzerland, the Inselspital, the University Hospital Basel, the University Hospital Lausanne, the Regional Hospital of Lugano and the Cantonal Hospital St. Gallen are participating in this study and have received ethical approval. In addition, since the start of the study in early November 2023, already 15 international centers have expressed their interest in participating. More centers worldwide will be contacted via a distribution list \[European Society of Minimally Invasive Neurological Therapy (ESMINT); Society of Neurointerventional Surgery (SNIS)\] and invited to participate. The investigators estimate that approximately 20-30 centers worldwide will participate with an estimated total sample size of 200-300 patients by 2025. The analysis will be based on a survey (see below for included data) specifically designed for this study and completed by local neuroradiologists, neurologists or neurosurgeons involved in the management of intracranial perforator aneurysms. The primary treating physician will review the clinical records of patients with intracranial perforator aneurysms treated conservatively, endovascularly, or surgically. Study lead and coordination as well as radiological and statistical analysis will be performed by the team at the Inselspital, Bern, Switzerland.
3.2 Baseline characteristics, imaging variables, treatment variables, and outcome variables
Data include:
* Age, sex, relevant comorbidities such as e.g. hypertension, arteriovenous malformation (AVM), Moya-Moya, initial clinical presentation (incidental vs. hemorrhagic). In case of hemorrhagic presentation the type of bleeding \[SAH, perimesencephalic subarachnoid hemorrhage (pmSAH), intraventricular hemorrhage (IVH), or intracerebral hemorrhage (ICH)\] will be documented.
* Type of initial diagnostic modality (CT, MRI, DSA).
* Perforator aneurysm identified on initial diagnostic modality.
* Type of treatment (surgical vs. endovascular). In case of endovascular treatment specific type \[coiling, n-butyl cyanoacrylate (NBCA), ethylene vinyl alcohol (EVOH), flow-diverter, Electro-coagulation, other\].
* Pre- and post-treatment modified Rankin Scale (mRS).
Clinical endpoints include:
* mRS at 3 months after initial diagnosis of an intracranial perforator aneurysm
* mRS at last follow-up (including time-point of last follow-up after diagnosis)
* Rupture/re-rupture of the index aneurysm as a time-event outcome
Safety endpoints include:
* Death during the acute hospital stay
* Death up to 90 days (related to the index aneurysm)
* Ischemic stroke (imaging based)
* Periprocedural and postprocedural complications in patients submitted to endovascular or surgical treatment.
Efficacy Endpoint
• For patients receiving treatment, assessment of aneurysm occlusion after treatment and available follow-ups.
3.3 Data transfer and storage (Medical-Blocks® and REDCap)
Imaging data from all external participating centers will be securely transferred via and stored on Medical-Blocks® (https://mb-neuro.medical-blocks.ch). This cloud-based platform for storage, anonymization and exchange of medical images in the neuro field (MB-Neuro) is provided by the Inselspital Bern. The platform provides the necessary interfaces to communicate with other secure and advanced IT environments via various Application Programming Interfaces (APIs). Secure Sockets Layers (SSL) with 256-bit encryption is used, which complies with the regulations of KlinV. (Verordnung über klinische Versuche) Art. 18 and HFV (Humanforschungsverordnung) Art. 5 of the Swiss Ordinance on the Storage of Health-Related Personal Data and Biological Materials. The clinical datasets will be provided in an anonymized fashion (matching the anonymized imaging data) by the physician primarily involved in patient management from the participating centers and entered and stored in REDCap.
4. Sample size and statistical analyses
This is an exploratory study. The investigators estimate that approximately 20-30 centers worldwide will participate with an estimated total sample size of 200-300 patients.
Categorical variables will be presented as numbers and percentages, and continuous variables as medians, interquartile range (IQR). Fisher's exact will be used for categorical and Mann-Whitney U test or Kruskal-Wallis test for continuous variables. Logistic regression results will be displayed as odds ratios (OR) for simple regression or adjusted OR (aOR) for multinomial regression analyses, with their corresponding 95% confidence intervals (CIs). As this is an exploratory study, no conclusions about significance can be drawn. Therefore, a p-value \< 0.05 will be interpreted as a trend. All analyses will be performed using established statistic software, including R 4.01 or newer, Python 3.83 or newer, Stata 16 and/or Statistical Package for the Social Sciences (SPSS) 27.00 or newer.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Aneurysm, Brain
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
CASE_ONLY
Study Time Perspective
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients from the Inselspital and from participating centers worldwide, who have been diagnosed or will be diagnosed with one or more lenticulostriate, basilar and/or other intracranial perforator aneurysms (starting from January 1st, 2013).
* Patients aged ≥18 years
* Written informed consent
* Patients aged ≥18 years
* Written informed consent
Exclusion Criteria
* Presence of documented written or verbal refusal.
* Aneurysm arising from the middle cerebral artery trunk which does not incorporate a lenticulostriate artery (Vargas Type 1), as they are not perforator aneurysms by strict definition.
* Aneurysm arising from the basilar artery trunk adjacent to a perforating branch but not involving a perforating artery (Satti Type 1), as they are not perforator aneurysms by strict definition.
* Aneurysm arising from the middle cerebral artery trunk which does not incorporate a lenticulostriate artery (Vargas Type 1), as they are not perforator aneurysms by strict definition.
* Aneurysm arising from the basilar artery trunk adjacent to a perforating branch but not involving a perforating artery (Satti Type 1), as they are not perforator aneurysms by strict definition.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Insel Gruppe AG, University Hospital Bern
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tomas Dobrocky, PD, MD
Role: PRINCIPAL_INVESTIGATOR
Institute of Diagnostic and Interventional Neuroradiology, Inselspital Bern
Johannes Kaesmacher, Prof, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Institute of Diagnostic and Interventional Neuroradiology, Inselspital Bern
Bettina L. Serrallach, MD
Role: PRINCIPAL_INVESTIGATOR
Institute of Diagnostic and Interventional Neuroradiology, Inselspital Bern
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Diagnostic and Interventional Neuroradiology, Inselspital Bern
Bern, , Switzerland
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Switzerland
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Elsheikh S, Mohlenbruch M, Seker F, Berlis A, Maurer C, Kocer N, Jamous A, Behme D, Taschner C, Urbach H, Meckel S. Flow Diverter Treatment of Ruptured Basilar Artery Perforator Aneurysms : A Multicenter Experience. Clin Neuroradiol. 2022 Sep;32(3):783-789. doi: 10.1007/s00062-021-01133-y. Epub 2022 Jan 20.
Reference Type
BACKGROUND
Gandhi CD, Gilad R, Patel AB, Haridas A, Bederson JB. Treatment of ruptured lenticulostriate artery aneurysms. J Neurosurg. 2008 Jul;109(1):28-37. doi: 10.3171/JNS/2008/109/7/0028.
Reference Type
BACKGROUND
Granja MF, Monteiro A, Agnoletto GJ, Jamal S, Sauvageau E, Aghaebrahim A, Hanel R. A systematic review of non-trunk basilar perforator aneurysms: is it worth chasing the small fish? J Neurointerv Surg. 2020 Apr;12(4):412-416. doi: 10.1136/neurintsurg-2019-015311. Epub 2019 Oct 9.
Reference Type
BACKGROUND
Hinojosa-Gonzalez DE, Ferrigno AS, Martinez HR, Farias JS, Caro-Osorio E, Figueroa-Sanchez JA. Aneurysms of the Lenticulostriate Artery: A Systematic Review. World Neurosurg. 2021 Jan;145:471-479.e10. doi: 10.1016/j.wneu.2020.08.160. Epub 2020 Sep 2.
Reference Type
BACKGROUND
Lu GD, Zhao LB, Jia ZY, Liu S. Micro-guidewire electrocoagulation for the treatment of intracranial aneurysms that are inaccessible by microcatheterization: a case series and review of the literature. J Neurointerv Surg. 2023 Dec;15(12):1229-1233. doi: 10.1136/jnis-2022-019355. Epub 2022 Oct 25.
Reference Type
BACKGROUND
Ma H, Zhao R, Fang Y, Li Q, Yang P, Huang Q, Xu Y, Hong B, Liu JM. Endovascular electrothrombosis: A promising alternative for basilar artery perforator aneurysm treatment. Interv Neuroradiol. 2021 Aug;27(4):511-515. doi: 10.1177/1591019920987913. Epub 2021 Jan 12.
Reference Type
BACKGROUND
Mutlu U, Kortman H, Boukrab I. A giant basilar artery perforator aneurysm. Radiol Case Rep. 2022 Jan 14;17(3):911-913. doi: 10.1016/j.radcr.2021.12.034. eCollection 2022 Mar.
Reference Type
BACKGROUND
Roccatagliata L, Pileggi M, Cianfoni A, Gralla J. Ruptured lenticulostriate artery aneurysm: a report of a case treated with endovascular embolisation. BMJ Case Rep. 2020 Oct 7;13(10):e236649. doi: 10.1136/bcr-2020-236649.
Reference Type
BACKGROUND
Shlobin NA, Cantrell DR, Ansari SA, Hurley MC, Shaibani A, Jahromi BS, Potts MB. Conservative Management and Natural History of Ruptured Basilar Perforator Artery Aneurysms: Two Cases and Literature Review. World Neurosurg. 2020 Jun;138:218-222. doi: 10.1016/j.wneu.2020.03.042. Epub 2020 Mar 16.
Reference Type
BACKGROUND
Vargas J, Walsh K, Turner R, Chaudry I, Turk A, Spiotta A. Lenticulostriate aneurysms: a case series and review of the literature. J Neurointerv Surg. 2015 Mar;7(3):194-201. doi: 10.1136/neurintsurg-2013-010969. Epub 2014 Feb 26.
Reference Type
BACKGROUND
Wu Y, Li Z, Yang D, Wu T, Chen A, Dai C, Zhu Q. Spontaneous subarachnoid hemorrhage caused by ruptured aneurysm of basilar trunk perforator: a case report and literature review. Chin Neurosurg J. 2022 Jun 10;8(1):14. doi: 10.1186/s41016-022-00281-5.
Reference Type
BACKGROUND
Young M, Schaible P, Asi K, Schaible K. Ruptured Distal Medial Lenticulostriate Artery Aneurysm Treated With Transcortical-Transventricular Approach. Cureus. 2021 Jul 5;13(7):e16186. doi: 10.7759/cureus.16186. eCollection 2021 Jul.
Reference Type
BACKGROUND
Kumagawa T, Otani N, Kakei Y, Negishi H, Suma T, Yoshino A. Ruptured Basilar Artery Perforator Aneurysm Definitely Diagnosed with Intraoperative Microsurgical Findings: Case Report and Literature Review. NMC Case Rep J. 2023 Jan 16;10:1-7. doi: 10.2176/jns-nmc.2022-0184. eCollection 2023.
Reference Type
BACKGROUND
van Gijn J, Rinkel GJ. Subarachnoid haemorrhage: diagnosis, causes and management. Brain. 2001 Feb;124(Pt 2):249-78. doi: 10.1093/brain/124.2.249.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-01778
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
NCT01885299
RECRUITING
FArial NErf MRI in the Preoperative Assessment of PArotide Tumors
NCT04613349
RECRUITING
Natural History Study of Patients With Neurofibromatosis Type I
NCT00924196
ACTIVE_NOT_RECRUITING
Hypofractionated Stereotactic Radiation Therapy of Brain Metastases: Evaluation of Whole-brain Radiotherapy
NCT02913534
COMPLETED
Intra-parotid Facial Nerve Tractography
NCT03950323
UNKNOWN
NA
Non Interventional German Leptomeningeal Disease Register
NCT06146010
RECRUITING
Long-term Cognitive and Functional Impact of Proton-therapy or Modern Fractionated Radiotherapy in Cavernous Sinus Meningioma: An Open-label Randomized 1:1 Phase III Study
NCT05895344
RECRUITING
NA
Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting With Spinal Canal Involvement (SCI)
NCT02559804
RECRUITING
Multimodal Diagnostic Assessment of Cerebral Gliomas With FET & FCH PET/CT, and Magnetic Resonance Imaging/Spectroscopy
NCT00939315
COMPLETED
Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
NCT03141021
RECRUITING
MRI Perfusion Curves Typology and Orbital Tumors (PERFORM)
NCT02434120
COMPLETED
PEComas: Natural History and Prognostic Factors
NCT03916575
UNKNOWN
Juvenile Recurrent Respiratory Papillomatosis: Establishment of a French National Cohort (PRR : National Cohort " REPA ")
NCT06000527
RECRUITING
Impact of Image-defined Risk Factors on the Outcome of Patients With Neuroblastoma: A Retrospective Study
NCT02558244
UNKNOWN
Multicenter Registry for Patients With Childhood.Onset Craniopharyngioma, Xanthogranuloma, Cysts of Rathke's Pouch, Meningioma, Pituitary Adenoma, Arachnoid Cysts
NCT04158284
RECRUITING
Prediction of Myocardial Injury After Laparoscopic Pheochromocytoma/ParaGangLioma Resection
NCT05752773
UNKNOWN
BIRN (Biomedical Informatics Research Network) Resources Facilitate the Personalization of Malignant Brain Tumor
NCT01124461
COMPLETED
Tuberous Sclerosis Complex Natural History Study: Renal Manifestations
NCT00598455
COMPLETED
Improvement of Local Control in Skull Base, Spine and Sacral Chordomas Treated by Surgery and Protontherapy Targeting Hypoxic Cells Revealed by [18F]FAZA) PET/CT Tracers
NCT02802969
COMPLETED
PHASE2
Genetic and Molecular Characterization of Nervous System Lesions
NCT06314607
RECRUITING
Secondary Central Nervous System Lymphoma Registry - Charité
NCT05114330
RECRUITING
Usefulness of Non EPI-DWI-MRI / CT 3D Static Co-registration Prior to Surgery of Cholesteatomas
NCT02903550
UNKNOWN
International Rare Brain Tumor Registry
NCT05697874
RECRUITING
Feasibility Study of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT in Glioblastoma's Patients
NCT03903419
UNKNOWN
NA
Adult Intracranial Ependymoma
NCT00920335
COMPLETED
NA